Voquezna now approved for heartburn associated with non-erosive GERD

FDA expanded the approval of vonoprazan (Voquezna) to include treatment of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) in adults. Approval was based on data from the phase 3 PHALCON-NERD-301 trial (N=772), in which the mean percentage of 24-hour heartburn-free days over 4 weeks of follow-up was 45% among adults treated with vonoprazan 10mg vs. 28% in the placebo group.